Merck & Co., Inc. (NYSE:MRK) Downgraded by Jefferies Financial Group to “Hold”

Jefferies Financial Group lowered shares of Merck & Co., Inc. (NYSE:MRK) from a strong-buy rating to a hold rating in a report issued on Wednesday,Zacks.com reports.

Several other equities research analysts also recently commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $142.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, July 8th. Daiwa Securities Group upgraded shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research note on Wednesday, August 12th. JPMorgan Chase & Co. boosted their target price on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, Argus lifted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $135.50.

Merck & Co., Inc. Price Performance

Merck & Co., Inc. stock opened at $152.21 on Wednesday. The firm has a fifty day moving average of $126.86 and a 200-day moving average of $120.74. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $153.50. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $375.53 billion, a P/E ratio of 121.77, a PEG ratio of 5.83 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. During the same quarter in the previous year, the business posted $2.13 EPS. The business’s quarterly revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be given a $0.85 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 272.00%.

Insiders Place Their Bets

In related news, EVP Chirfi Guindo sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the sale, the executive vice president directly owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP David R. Maraldo sold 18,706 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.72, for a total value of $2,407,836.32. Following the transaction, the executive vice president owned 18,212 shares in the company, valued at $2,344,248.64. This trade represents a 50.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 228,238 shares of company stock worth $29,977,783. Corporate insiders own 0.17% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. D.A. Davidson & CO. lifted its stake in shares of Merck & Co., Inc. by 4.4% in the 4th quarter. D.A. Davidson & CO. now owns 576,959 shares of the company’s stock worth $60,731,000 after acquiring an additional 24,576 shares during the period. Pinnbrook Capital Management LP increased its stake in shares of Merck & Co., Inc. by 95.2% during the fourth quarter. Pinnbrook Capital Management LP now owns 23,280 shares of the company’s stock valued at $2,450,000 after acquiring an additional 11,355 shares during the period. Cibc World Market Inc. raised its holdings in Merck & Co., Inc. by 32.6% during the fourth quarter. Cibc World Market Inc. now owns 1,301,744 shares of the company’s stock worth $137,022,000 after purchasing an additional 320,143 shares in the last quarter. Handelsbanken Fonder AB lifted its position in Merck & Co., Inc. by 13.9% in the fourth quarter. Handelsbanken Fonder AB now owns 1,843,042 shares of the company’s stock worth $193,999,000 after purchasing an additional 224,752 shares during the period. Finally, Panagora Asset Management Inc. lifted its position in Merck & Co., Inc. by 410.5% in the fourth quarter. Panagora Asset Management Inc. now owns 705,442 shares of the company’s stock worth $74,255,000 after purchasing an additional 567,249 shares during the period. 76.07% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The combination of Moderna’s individualized vaccine, intismeran, and Keytruda significantly extended the time high-risk melanoma patients remained free of recurrence and reduced the risk of cancer spreading compared with Keytruda alone. The result is viewed as the first positive late-stage validation of a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The data strengthen Merck’s oncology pipeline and could help offset concerns about the expected expiration of Keytruda’s patent later this decade. The companies are also studying similar vaccine approaches in lung, pancreatic, breast and other cancers, potentially expanding the commercial opportunity if regulators approve the treatment; approval is targeted for 2027. Moderna, Merck breakthrough could usher in wave of cancer vaccines
• Positive Sentiment: Investor enthusiasm was reflected in unusually heavy options activity, with 68,587 Merck call options purchased—about 188% above typical daily volume—suggesting increased bullish speculation, though options activity is not a fundamental performance measure.
• Neutral Sentiment: Broader bond-market relief supported interest-rate-sensitive equities and healthcare stocks, providing a favorable market backdrop for MRK. Stock Market Today, Aug. 19
• Negative Sentiment: Jefferies downgraded MRK from “strong buy” to “hold.” The call could limit further upside and reflects a more cautious analyst view after the stock’s strong run toward its 52-week high, although the firm’s specific rationale was not provided.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.